MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
XOMA Corporation ROE Ratio 2011-2026 | XOMA
Annual ROE Ratio XOMA Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.78 | -22.33 | -46.02 | -13.79 | 11.14 | 15.39 | -4.51 | -71.03 | 252.26 | 113.39 | 892.42 | -1235.91 | 3111.56 | -331.04 | -218.13 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3111.56 | -1235.91 | 166.08 |
Quarterly ROE Ratio XOMA Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.85 | -37.74 | -30.44 | -17.06 | -22.26 | -0.85 | -25.74 | -18.67 | -21.88 | -19.88 | -18.44 | -8.3 | -12.27 | -13.04 | -11.5 | -14.92 | 11.31 | 14.04 | 11.87 | 15.39 | -20.66 | -12.19 | -17.36 | -4.51 | -10.72 | -42.31 | -43.42 | -71.03 | -77.78 | 401.9 | 417.19 | 252.26 | 312.07 | -116.71 | -89.52 | 113.39 | -1021.56 | -1027.3 | -30.44 | 892.42 | 1754.2 | 1268.78 | -144.09 | -1235.91 | 311.96 | 1519.61 | 2336.12 | 3111.56 | 1810.85 | 942.75 | 434.89 | -331.04 | -420.24 | -338.75 | -317.65 | -218.13 | -43.59 | -54.16 | -42.2 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3111.56 | -1235.91 | 168.36 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.85 | 3.24 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 322.18 | -3.36 % | $ 42.2 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.71 | -0.53 % | $ 766 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 3.51 | 3.09 % | $ 353 M | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 7.72 | 4.04 % | $ 76.3 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 22.0 | 1.48 % | $ 1.03 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 101.75 | 2.29 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.25 | -12.11 % | $ 144 M | USA |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-16.39 | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 8.6 | -1.04 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.28 | 0.94 % | $ 458 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.69 | -3.64 % | $ 3.01 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.59 | 6.71 % | $ 423 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
|
Immatics N.V.
IMTX
|
1.79 | $ 10.8 | -1.86 % | $ 679 M | Germany |
 |
Caladrius Biosciences
CLBS
|
-67.58 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
204.15 | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 33.63 | -0.72 % | $ 2.23 B | USA |